Elikon Venture
VC Fund
Elikon Venture is a venture capital firm.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Elikon Venture invests in
Stages Elikon Venture invests in
Countries Elikon Venture invests in
Investment Focus
Industry
- Biotechnology 6 (50%)
- Medical 5 (42%)
- Pharmaceutical 4 (33%)
- Health Care 3 (25%)
- Therapeutics 3 (25%)
Stage
- Series A 4 (33%)
- Series B 3 (25%)
- Seed 2 (17%)
- Series C 2 (17%)
- Venture - Series Unknown 1 (8%)
Country
- China 5 (42%)
- United States 4 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CORE Biomedicine
|
CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M / Series A / Jul 28, 2026 | |
Oricell Therapeutics
|
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $110M / Venture - Series Unknown / Apr 09, 2026 | |
Fortitude Biomedicines
|
Fortitude Biomedicines is a biotechnology company that develops antibody-based biologic drugs targeting autoimmune diseases. | $13M / Seed / Jan 26, 2026 | |
|
Oricell Therapeutics
|
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $70M / Series C / Jan 12, 2026 | |
Angitia Biopharmaceuticals
|
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $120M / Series C / Dec 11, 2024 | |
|
Angitia Biopharmaceuticals
|
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $46M / Series B / Oct 19, 2023 | |
Innovac Therapeutics
|
Innovac Therapeutics operates as a biotechnology company dedicated to developing innovative vaccines for patients with unmet medical needs, using our proprietary RNA technology platforms and manufacturing capabilities. | $18M / Seed / Sep 01, 2023 | |
Eccogene
|
Eccogene is a Health Care Company. | $25.2M / Series B / Jun 12, 2023 | |
Allorion Therapeutics
|
Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses. Allorion operates two locations in Natick, Massachusetts, and Guangzhou, China. | $50M / Series B / Mar 09, 2023 | |
Ucello Therapeutics
|
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $25M / Series A / Feb 10, 2022 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Elikon Venture invest in?
Elikon Venture invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Elikon Venture last invest?
The most recent investment recorded for Elikon Venture closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
